1/15/2020 Prevention of REnal and Vascular ENd-stage Disease | Maelstrom research

Studies / Individual Studies / Prevention of REnal and Vascular ENd-stage Disease

Prevention of REnal and Vascular

ENd-stage Disease

The PREVEND Study is a prospective, observational cohort study, focussed to assess the impact of elevated urinary albumin loss in
non-diabetic subjects on future cardiovascular and renal disease. PREVEND is an acronym for Prevention of REnal
and Vascular ENd-stage Disease. This study started with a population survey on the prevalence of micro-albuminuria and
generation of a study cohort of the general population. The goal is to monitor this cohort for the long-term development of cardiac-,
renal- and peripheral vascular end-stage disease. For that purpose the participants receive questionnaires on events and are seen
every three/four years for a survey on cardiac-, renal- and peripheral vascular morbidity.

Search Variables

Overview
Acronym PREVEND

Website PREVEND Website

Investigators Dr. Hans Hillege (University of Groningen)

Contacts Dr. Hans Hillege (University of Groningen)

Study Design
Study Design Cohort


https://www.maelstrom-research.org/mica/individual-study/prevend 1/5
1/15/2020 Prevention of REnal and Vascular ENd-stage Disease | Maelstrom research

Recruitment Target Individuals

Number of Participants 8,592

Number of Participants 8,592

with Biosamples

Supplementary
Of the 85,421 subjects invited 40,856 responded (=48%) . We invited all consenting
Information subjects with a morning urinary albumin concentration (UAC) of >10 mg/L (n=7,768)
and an a-select sample of those with an UAC <10 mg/L (n=3,395) for further studies
. Of these invitees 8,592 subjects completed the first screening, that was held in
1997/1998

Access
 Yes
 No
− Not Applicable
 Don't know

General Information

Availability of data and biosamples

Possible Access to Data 

Possible Access to Biosamples 

Other −

Marker Paper
Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. Pinto-Sietsma SJ,
Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. J Am Soc Nephrol. 2000 Oct;11(10):1882-8

PUBMED 11004219

Study Timeline

Each colour in the timeline graph below represents a separate Study Population, while each segment in the graph represents
a separate Data Collection Event. Clicking on a segment gives more detailed information on a Data Collection Event.

https://www.maelstrom-research.org/mica/individual-study/prevend 2/5
1/15/2020 Prevention of REnal and Vascular ENd-stage Disease | Maelstrom research

1997 1998 1999 2000 2001 2002 2003 2004 2005

PREVEND cohort

Population
PREVEND cohort
The Prevend cohort is enriched for the presence of an elevated urinary albumin excretion (UAE). The population is formed of
Groningen inhabitants aged 28 to 75 years, who agreed to give a morning urine and to answer a short questionnaire. Of the
85,421 subjects invited to participate, 40,856 responded. The final sample is constisted of 8,592 consenting subjects with a
morning urinary albumin concentration (UAC) of >10 mg/L and an a-select sample of those with an UAC <10 mg/L who
completed the first screening. Pregnant women and participants with diabetes mellitus were excluded.

Sources of Recruitment

General Population Volunteer enrolment

Selection Criteria

Age Minimum age 18, Maximum age 75

Country Netherlands

Ethnic Origin Caucasian

Sample Size

Number of Participants 8,592

Number of Participants 8,592

with Biosamples

Data Collection Events

Name Description Start End

NC1 The subjects were seen for two visits at the... 1997 1998

Second screening First follow-up of the participants. The same... 2001 2003

Third screening Second follow-up of the participants. The same... 2003 2006

Fourth Screening To be completed... 2009 2012

https://www.maelstrom-research.org/mica/individual-study/prevend 3/5
1/15/2020 Prevention of REnal and Vascular ENd-stage Disease | Maelstrom research

Networks
Acronym Name Studies

BioSHaRE- Biobank Standardisation and Harmonisation for Research Excellence in the European 10
EU Union

Maelstrom Research
The Research Institute of the McGill University Health Centre (RI MUHC)
Montreal General Hospital
1650 Cedar Ave. Floor 3, R3-110.3
R Building (Côte-des-Neiges/Avenue des Pins entrance)
Montreal, QC, H3G 1A4, Canada
 info@maelstrom-research.org

Follow Us on Twitter

@MaelstromRsrch

Home
About Us
Background
Our Team
Publications
Funding
FAQ
About Harmonization
Why Harmonize
Maelstrom Guidelines 

Methods Library

https://www.maelstrom-research.org/mica/individual-study/prevend 4/5
1/15/2020 Prevention of REnal and Vascular ENd-stage Disease | Maelstrom research

What We Offer
Expert Advice
Software
Metadata Catalogues
Harmonization Platforms
Partnerships
Current Partnerships
Past Partnerships
External Users
Contact Us
Maelstrom Catalogue
Networks
Individual Studies
Harmonization Studies
Search

© 2020 Maelstrom Research. All rights reserved. Terms and Conditions Powered by Mica


https://www.maelstrom-research.org/mica/individual-study/prevend 5/5